Could CAR-T cells tame severe colitis? early trial launches

NCT ID NCT07435779

Recruiting now Disease control Sponsor: Hebei Senlang Biotechnology Inc., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether a patient's own immune cells, engineered to target BCMA and/or CD19, can calm severe ulcerative colitis that hasn't responded to other treatments. Twelve adults with moderate-to-severe active disease will receive a single infusion of these CAR-T cells. The main goal is to check safety and see if it leads to clinical remission within 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR-T cells (BCMA, CD19, or both) made from the patient's own blood
What this could lead to: If it works, this could point toward a new treatment for severe ulcerative colitis that doesn't respond to standard therapies.
What could go wrong: This is a very early, small trial with only 12 people. CAR-T therapy can cause serious side effects like cytokine release syndrome and nerve problems. It may not work or may be too risky.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis urea cycle disorder urethra transitional cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UC

Contacts and locations

Locations

Foresea Life Insurance Guangzhou General Hospital
RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.